Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

50 results about "Genetically modified bacteria" patented technology

Genetically modified bacteria were the first organisms to be modified in the laboratory, due to their simple genetics. These organisms are now used for several purposes, and are particularly important in producing large amounts of pure human proteins for use in medicine.

Genetically modified bacteria with high yield of sophorolipids, construction method and application thereof

The present application relates to the technical field of genetic engineering, and in particular to a high-yield sophorolipid gene knockout engineering bacterium, a construction method thereof and an application, the engineering bacterium taking Bombus bornensis Candida as a starting strain, and using a gF-Hph-gR nucleotide sequence to replace a gene sequence seq2 in a sophorolipid synthesis path for regulating a lactonization reaction , The gF-Hph-gR nucleotide sequence is SEQ ID No. 1, and the seq2 gene sequence is SEQ ID No. 2. The method provided by the present application uses fusion PCR to construct a seq2 gene knockout box with a resistance screening marker, and the shortest time required is 1 day, which provides a new way for efficiently constructing a sophorolipid production engineering strain. The high-yield sophorolipid gene knockout strain provided by the present application lays a foundation for large-scale industrial production of sophorolipid and meets market demand, and has a wide application prospect, economic value and social benefit.
Owner:GUANGZHOU LIBY ENTERPRISE GROUP CO LTD

A method of treating skin conditions using genetically modified microorganisms.

This disclosure relates to compositions and methods using genetically modified bacteria that express superoxide dismutase (SOD) and catalase enzymes to reduce oxidative stress in the skin, and can be used for various skin conditions. In some embodiments of this disclosure, the genetically modified bacteria are Gram-positive bacteria, for example, of the genus Corynebacterium.
Owner:RESVITA BIOINCORPORATED

Modified clostridium bacteria capable of producing propan-2-ol, preparation and use thereof

The present invention relates to the genetic modification of a bacterium of the genus Clostridium, generally a solvent-producing bacterium of the genus Clostridium, in order to allow the production of propan-2-ol or a mixture comprising propan-2-ol and ethanol by said bacterium. Furthermore, methods, tools and kits for obtaining said bacteria, the genetically modified bacteria obtained and uses thereof are described.
Owner:IFP ENERGIES NOUVELLES

Improved taurine biosynthesis using genetically modified bacteria

PCT designated stageWO2026011242A1BacteriaHydrolasesTaurine synthesisCysteamine
A genetically modified prokaryotic cell to express enzymes involved in the production of taurine. Said prokaryote comprises a vanin selected from: vanin- 1 (vnn-1), vanin-2 (vnn-2), or vanin- 3 (vnn-3), a cysteamine dioxygenase (ado), and a flavin-containing monooxygenase 1 (fmol), in addition to either the addition, alteration, or deletion of at least one gene involved in taurine synthesis or transport.
Owner:CHEM EVOLUTION LTD

Systems and methods for identifying microbiomic treatment for hereditary and metabolic diseases

Disclosed herein are methods and systems ofscreening for microbiomics treatments for hereditary diseases or metabolic diseases using high-throughput nematode models. Genetically modified bacteria with therapeutic potential in treating certain hereditary diseases or metabolic diseases, compositions comprising such bacteria, as well as methods of uses such bacteria are also disclosed herein.
Owner:FUDAN UNIVERSITY

High purity polyhydroxybutyrate (PHB) production and economic purification process from genetically modified bacteria

The present invention provides genetically modified Gram-positive bacteria that efficiently produce polyhydroxyalkanoates (PHAs). Also provided in the present description is a DNA molecule encoding enzymes necessary for the synthesis of PHAs. The invention further provides methods of producing PHAs comprising cultivating a genetically modified Gram-positive bacterium that produces polyhydroxyalkanoates (PHAs) efficiently and procedure for purification of PHA from a culture of a genetically modified Gram-positive bacterium that produces polyhydroxyalkanoates (PHAs).
Owner:INGENIERÍA METABÓLICA SA +2

Taurine biosynthesis using genetically modified bacteria

PendingUS20260015622A1BacteriaHydrolasesTaurine biosynthesisGenetically modified bacteria
A genetically modified prokaryotic cell comprising:at least one of the following:i. an addition, deletion and / or alteration of at least one gene to promote to taurine production; andii. an addition, deletion and / or alteration of at least one gene related to taurine cellular transportation; andat least one of the following polynucleotide sequences:i. a vanin (vnn) polynucleotide sequence selected from the group consisting of:vanin-1 (vnn1), wherein said vnn1 polynucleotide sequence has at least 70% sequence coverage to SEQ 3 or SEQ 98, and at least 70% sequence identity to SEQ 3 or SEQ 98;vanin-2 (vnn2), wherein said vnn2 polynucleotide sequence has at least 70% sequence coverage to SEQ 100, and at least 70% sequence identity to SEQ 100; andvanin-3 (vnn3), wherein said vnn3 polynucleotide sequence has at least 70% sequence coverage to SEQ 141, and at least 70% sequence identity to SEQ 141;ii. a cysteamine dioxygenase (ado) polynucleotide sequence which has at least 70% sequence coverage to SEQ 1, and at least 70% sequence identity to SEQ 1; andiii. a flavin-containing monooxygenase 1 (fmo1) polynucleotide sequence which has at least 70% sequence coverage to SEQ 5 or SEQ 99, and at least 70% of sequence identity to SEQ 5 or SEQ 99.
Owner:CHEM EVOLUTION LTD

Compositions and methods for increasing secretion of molecules

Aspects herein relate, in part, to genetically modified bacteria capable of secreting protein of interest using signal peptides. Aspects herein also relate, in part, to presenting proteins of interest on a bacterial cell using truncated cell surface proteins.
Owner:UNIVERSITY OF CHICAGO

Optimized genetic tools for modifying bacteria

The present invention relates to the transformation and genetic modification of bacteria belonging to the phylum Firmicutes. The present invention therefore relates to methods, tools and kits allowing such genetic modification, in particular to nucleic acid sequences for facilitating the transformation of said bacteria, said sequences comprising i) all or part of the sequence SEQ ID NO: 126, and ii) sequences allowing the modification of the genetic material of the bacteria and / or the expression in said bacteria of DNA sequences partially or completely absent in the genetic material present in the wild-type version of said bacteria. The present invention also relates to the genetically modified bacteria obtained and to their use, in particular for the production of solvents, preferably on an industrial scale.
Owner:IFP ENERGIES NOUVELLES

Genetically modified Clostridium bacteria, their preparation and use

The present invention relates to the genetic modification of Clostridium bacteria, in general solvent-producing bacteria of the genus Clostridium, in particular bacteria which, in the wild state, have a gene encoding an amide alcohol-O-acetyltransferase. The present invention therefore relates to methods, tools and kits which allow such genetic modifications, in particular the elimination or modification of sequences encoding or controlling the transcription of an amide alcohol-O-acetyltransferase, to the genetically modified bacteria obtained, and to their use, in particular preferably on an industrial scale, for the production of solvents.
Owner:IFP ENERGIES NOUVELLES

Oral vaccine via dental bacteria and emitted peptides to prevent COVID-19 infection

Disclosed is a pharmaceutical composition to prevent transmission of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the pharmaceutical composition comprising: genetically modified bacteria; sequences of small peptides; and pharmaceutical excipients, wherein the genetically modified oral bacteria are modified to translate, produce, and emit the sequences of small peptides which neutralize SARS-CoV-2 against COVID-19, wherein transgenic technology is used to modify the genetically modified oral bacteria to add genes in genetically modified oral bacteria that are transcribed to produce small peptides from the sequences of small peptides so added, wherein the sequences of small peptides show extreme binding and neutralization to SARS-CoV-2 but not to host proteins or processes, and wherein the pharmaceutical excipients aid the oral and / or nasal administration of the pharmaceutical composition.
Owner:KOTLYAR DAVID

SUGAR PRODUCTION BY PERIPLASMIC ALDOLIZATION

ActiveFR3118773B1Rare sugarGenetically modified bacteria
The invention relates to a polypeptide comprising a bacterial membrane anchoring peptide and an aldolase capable of catalyzing an aldol condensation reaction between two selected compounds to form a sugar. The aldolase may be dependent on dihydroxyacetone phosphate (DHAP) or dihydroxyacetone (DHA). The invention also relates to a bacterium genetically modified to produce sugars, particularly rare sugars, phosphorylated or not, and a method for producing and secreting these sugars by culturing said bacterium in a suitable culture medium M1 comprising two compounds capable of forming a sugar by an aldol condensation reaction.
Owner:BIOC3

Genetically modified bacteria and methods for genetic modification of bacteria

Microbes can be genetically modified to express biomolecules that are beneficial to mammals and / or to reduce, or eliminate, expression of harmful virulence factors. The growth and viability of such genetically modified microbes can optionally be controlled by inducible promoters that regulate the expression of proteins that are essential to their growth and survival. Compositions comprising such genetically modified microbes as well as methods of making and using the same are disclosed herein.
Owner:CROWN LABORATORIES INC

Biosynthesis of sulfur-containing compounds using genetically modified bacteria

PCT designated stage expiredWO2025015413A1BacteriaHydrolasesCysteamineSulphur compound
A genetically modified prokaryotic cell which comprises: a cysteamine dioxygenase (ADO) polypeptide sequence which has at least 70% sequence coverage to SEQ 2, and at least 25 % sequence identity to SEQ 2; and a vanin (VNN) polypeptide sequence selected from the group consisting of: a vanin- 1 (VNN1) polypeptide sequence which has at least 70% sequence coverage to SEQ 4, and at least 25 % sequence identity to SEQ 4; a vanin-2 (VNN2) polypeptide sequence which has at least 70% sequence coverage to SEQ 84, and at least 25 % sequence identity to SEQ 84; and a vanin-3 (VNN3) polypeptide sequence which has at least 70% sequence coverage to SEQ 128 and at least 25 % sequence identity to SEQ 128.
Owner:CHEM EVOLUTION LTD

Genetically modified bacteria for improved pest control of plants

The present disclosure relates to edited (genetically modified) microorganisms comprising consortia of microorganisms, and to agricultural compositions comprising said microorganisms, intended to increase the tolerance of plants to nematode pests and / or to directly reduce nematode populations in soil or root systems. In addition, the present disclosure teaches methods of utilizing the described microorganisms, microbial consortia, and agricultural compositions comprising the same in methods of conferring beneficial properties to target plant species. In particular aspects, the present disclosure provides methods for improving desired plant traits and reducing undesired pests that affect crop performance in agronomically important crop species.
Owner:BIOCONSORTIA INC

Genetically modified bacteria producing three DNA repair enzymes and method for the evaluation of DNA repair activity

Three recombinant E. coli strains produce the enzymes CPD-photolyase, 6,4-bifunctional photolyase and 6,4-photolyase, from bacterial Antarctic isolates of the genus Hymenobacter the first one and Sphingomonas the others. It is also disclosed a process of production and purification of the recombinant enzymes with high performance, high degree of purity and high catalytic repair activity, having applications in, but it is not limited to, cosmetics and pharmaceutical industry. A fast, cheap and qualitative method is provided for the determination of the CPD photolyase activity.
Owner:UNIV DE LA REPUBLICA +1

Transaminase mutant and its use in the preparation of a sitagliptin intermediate

UndeterminedES3073041T3ThreonineTyrosine
A mutant transaminase and its use in the preparation of a sitagliptin intermediate are provided. The mutant is obtained by substituting tyrosine at position 74 with proline, glutamic acid at position 228 with aspartic acid, leucine at position 254 with alanine, and methionine at position 290 with threonine in the amino acid sequence shown in SEQ ID NO: 2. The sitagliptin intermediate or sitagliptin ester is prepared using wet thallus or a pure enzyme obtained by fermentation and culture of genetically modified bacteria containing a gene encoding the mutant transaminase as a biocatalyst, and using a ketone precursor of the sitagliptin intermediate or a prochiral carbonyl compound as a substrate. The overall yield is approximately 82%, and the ee value of the product can reach up to 99%.

Genetically modified bacteria for multi-modal secretion of a neoantigen

A vaccine and methods of treatment thereof, wherein the vaccine comprises a recombinant Gram-negative bacteria genetically modified to express a first antigen fusion peptide comprising a neoantigen or series thereof, said neoantigen or series thereof associated with a first secretion signal from a double membrane-spanning secretion system and a second antigen fusion peptide comprising a homologous neoantigen or series thereof, associated with a second secretion signal from an outer membrane-spanning secretion system. The Gram-negative bacteria may be further modified for quadmodal transport. Specifically, the fusion peptides include signal peptides are each associated with a Type III (T3SS) and a Type V (T5SS) secretion system.
Owner:BACCINE LTD +1

Modified clostridium autoethanogenum bacteria, their preparation and use

PendingCN123036377ABiotechnologyClostridium autoethanogenum
The present invention relates to genetic modifications of Clostridial bacteria, typically solventogenic Clostridial bacteria, to enable said bacteria to produce ethanol. Methods, tools and kits for obtaining said bacteria, the obtained genetically modified bacteria and uses thereof are also described.
Owner:IFP ENERGIES NOUVELLES

Clostridium bacteria modified to assimilate several sugars simultaneously, and preparation and use thereof

The present invention relates to a genetically modified bacterium of the genus Clostridium, in particular a solvent-producing bacterium of the genus Clostridium. The invention also relates to methods, tools and kits for deleting or modifying one or more coding sequences of a XylR and / or AraR transcriptional repressor or for controlling transcription of one or more coding sequences of a XylR and / or AraR transcriptional repressor, the genetically modified bacteria obtained and uses thereof, the present invention relates to a carbon-containing composition, in particular for the simultaneous fermentation of at least one hexose and one pentose or of at least two carbon-containing substrates selected from the group consisting of glucose, arabinose, xylose, mannose and galactose.
Owner:IFP ENERGIES NOUVELLES

Genetically modified bacteria for multi-modal secretion of neoantigens

A vaccine and methods of treatment thereof wherein the vaccine comprises a recombinant Gram-negative bacterium genetically modified to express a first antigen fusion peptide comprising a neoantigen or series thereof, and a second antigen fusion peptide comprising a neoantigen or series thereof, the first antigen fusion peptide comprising a recombinant Gram-negative bacterium, the recombinant Gram-negative bacterium comprising a recombinant Gram-negative bacterium, the recombinant Gram-negative bacterium comprising a recombinant Gram-negative bacterium, and the recombinant Gram-negative bacterium comprising a recombinant Gram-negative bacterium. The neoantigen or series thereof is associated with a first secretion signal from a cross-bimembrane secretion system; the second antigen fusion peptide comprises a homologous neoantigen or series thereof, the homologous neoantigen or series thereof being associated with a second secretion signal from the transadventitia secretion system. The gram-negative bacteria may be further modified for four-mode transport. In particular, fusion peptides comprising a signal peptide are each associated with a type III secretion system (T3SS) and a type V secretion system (T5SS).
Owner:BESIAN LTD +1

Modified clostridium bacteria, genetic editing tool for pSOL plasmids of clostridium bacteria and uses thereof

The present invention relates to the genetic modification of a bacterium of the genus Clostridium, typically a solvent-producing bacterium of the genus Clostridium, and to possible uses of a genetic editing tool suitable for modifying a pSOL megaplasmid within said bacterium. The invention also relates to methods, tools and kits allowing the deletion, modification or insertion of one or more product-of-interest coding sequences or controlling the transcription of one or more product-of-interest coding sequences, the genetically modified bacteria obtained and their use, in particular for the production of bio-based molecules such as biofuels.
Owner:IFP ENERGIES NOUVELLES

Systems, tools and methods for engineering bacteria

The present invention relates to a system, a tool and a method for engineering bacteria. The present invention relates in particular to a specific relative configuration of different elements that allows and is convenient to use for robust genome modification of bacterial genomes. In certain embodiments of the system, the tool and the method, genetically modified bacteria can be obtained that do not contain any scar sequence. A further aspect of the present invention relates to an innovative inducible expression system suitable for obtaining regulated gene expression in bacteria.
Owner:プルモバイオティクスエスエル

Recovery of anthropogenic precious metals and toxic metals using synthetic biological leaching methods.

This invention provides a method for using enzymes to cyanide a metal and reduce the metal-cyanide complex, as well as a method for using biological techniques to hydrolyze cyanide. [Solution] The present invention relates to the use of genetically modified bacteria in a process comprising the generation of cyanide, the reduction of leached metal ions, the decomposition of cyanide, and the subsequent reuse of cyanide. Furthermore, it provides a transcriptional regulatory tool in Chromobacterium violaseum. In one embodiment, the present invention provides a genetically modified bacterium that is isolated and transformed by at least one polynucleotide molecule, wherein the polynucleotide molecule comprises a heterologous mercury(II) reductase (MerA) gene operably linked to at least one promoter, and comprises at least one mutation in which a metal ion is reduced by the gene product of the MerA gene to produce a metal element as metal nanoparticles.
Owner:NATIONAL UNIVERSITY OF SINGAPORE

Method for the production of apocarotenoids and uses thereof in the food, cosmetic, nutraceutical and pharmaceutical sector

The invention provides methods and materials for recombinantly producing apocarotenoids in bacteria and transgenic plants, wherein said transgenic organisms expressing at least one heterologous gene from a plant species selected from Handroanthus impetiginosus, Paulownia tomentosa, and / or Physalis peruviana. Moreover, the present invention also relates to the genetic constructs comprising the at least one heterologous gene, at least a plasmid and / or at least a vector comprising the same, their use for the expression in bacteria and plants, and methods for obtaining such genetically modified bacteria and plants, which have a high concentration of apocarotenoids compounds, in particular crocins and picrocrocins. Furthermore, the present disclosure also refers to the compositions comprising such apocarotenoids products obtained and uses thereof.
Owner:UNIV DE CASTILLA LA MANCHA

Genetically modified Methylobacillus bacteria having improving properties

The present invention generally relates to the biotechnology engineering, and specifically to genetically modified bacteria of the genus Methylobacillus which have improved properties making them particularly useful in large scale methanol fermentations. More specifically, the present invention provides a bacterium of the genus Methylobacillus which has been modified to have a decreased production of exopolysaccharides (EPS) compared to an otherwise identical bacterium that does not carry said modification. The present invention further provides a method for producing a biochemical compound using a genetically modified bacterium of the present invention.
Owner:ACIES BIO D O O

Method of generating pulcherrimin and pulcherriminic acid and uses thereof

A composition of matter comprising genetically modified bacteria of the Bacillus genus which over-express cyclodipeptide synthase (YvmC) and / or cytochrome P450 oxidase (CypX) is disclosed. The bacteria synthesize at least twice the amount of pulcherriminic acid as compared to the amount synthesized in a non-genetically modified bacteria of a corresponding strain.
Owner:NORTHEASTERN UNIV (US) +1

Use of modified Escherichia coli and its L-amino acids in fermentation production

PendingJP2026521933AEscherichia coliTransgene
This paper discloses the use of modified Escherichia coli and its L-amino acid fermentation production. Specifically, it discloses the use of pyruvate formate lyase, alcohol dehydrogenase, branched-chain amino acid transaminase derived from Escherichia coli, branched-chain amino acid transaminase derived from Bacillus subtilis, thiamine phosphate synthase, and maleate dehydrogenase in the construction of genetically modified bacteria that produce L-amino acids. Experiments have shown that by knocking out the genes encoding pyruvate formate lyase, alcohol dehydrogenase, branched-chain amino acid transaminase derived from Escherichia coli, thiamine phosphate synthase, and maleate dehydrogenase in E. coli capable of producing L-amino acids, and introducing the gene encoding branched-chain amino acid transaminase derived from Bacillus subtilis, recombinant bacteria favorable for L-amino acid accumulation can be obtained. These recombinant bacteria can significantly increase L-amino acid production and reduce costs, which is of great significance in accelerating the industrialization process of L-amino acids.
Owner:NINGXIA EPPEN BIOTECH CO LTD

Genetically modified microorganism, method(s) and application(s) thereof

PendingUS20260078386A1Haemoglobins/myoglobinsTransferasesHeme synthesisMicroorganism
The present disclosure relates to genetically modified bacteria, wherein said genetically modified bacteria is designed to express or overexpress a heme-containing protein. Said protein is optionally expressed or overexpressed in combination with one or more enzymes that catalyze the heme synthesis pathway. Said genetically modified organism allows scalable production of heme-containing protein with the advantage that the expressed protein remains in soluble form without forming inclusion bodies.
Owner:RELIANCE IND LTD